$BLUE
bluebird bio, Inc.

2018 Q3 Form 10-Q Financial Statement

#000156459018026258 Filed on November 01, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q4 2017 Q3
Revenue $11.53M $4.168M $7.711M
YoY Change 49.5% 168.56% 396.84%
Cost Of Revenue $29.00K $0.00 $1.100M
YoY Change -97.36%
Gross Profit $11.50M $4.200M $6.611M
YoY Change 73.94%
Gross Profit Margin 99.75% 100.77% 85.73%
Selling, General & Admin $44.50M $29.10M $23.00M
YoY Change 93.48% 79.63% 57.53%
% of Gross Profit 386.99% 692.86% 347.91%
Research & Development $116.7M $92.60M $61.55M
YoY Change 89.69% 62.17% -3.84%
% of Gross Profit 1015.25% 2204.76% 930.95%
Depreciation & Amortization $4.410M $3.640M $3.620M
YoY Change 21.82% 44.44% 52.1%
% of Gross Profit 38.35% 86.67% 54.76%
Operating Expenses $161.3M $120.9M $85.37M
YoY Change 89.0% 63.68% 7.12%
Operating Profit -$149.8M -$116.8M -$77.66M
YoY Change 92.92% 61.43% -0.62%
Interest Expense $4.591M $500.0K -$1.155M
YoY Change -497.49% -183.33% 5.0%
% of Operating Profit
Other Income/Expense, Net -$252.0K -$100.0K $8.000K
YoY Change -3250.0% -111.11% -99.11%
Pretax Income -$145.5M -$117.0M -$78.81M
YoY Change 84.61% 63.87% 2.08%
Income Tax $106.2M $0.00
% Of Pretax Income
Net Earnings -$145.5M -$117.2M -$78.81M
YoY Change 84.61% 64.27% 2.31%
Net Earnings / Revenue -1261.97% -2812.57% -1021.98%
Basic Earnings Per Share
Diluted Earnings Per Share -$2.730M -$2.515M -$1.728M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.675B $1.290B $728.8M
YoY Change 129.87% 83.15% 21.26%
Cash & Equivalents $952.1M $758.5M $251.7M
Short-Term Investments $723.1M $531.6M $490.8M
Other Short-Term Assets $30.00M $29.60M $27.20M
YoY Change 10.29% 859.48% 244.3%
Inventory
Prepaid Expenses $24.13M $21.17M
Receivables $4.635M
Other Receivables
Total Short-Term Assets $1.725B $1.323B $758.7M
YoY Change 127.41% 82.65% 24.62%
LONG-TERM ASSETS
Property, Plant & Equipment $232.9M $199.6M $182.4M
YoY Change 27.67% 27.17% 38.46%
Goodwill $13.13M $13.13M
YoY Change 0.0%
Intangibles $14.11M $16.93M
YoY Change -18.18%
Long-Term Investments $323.8M $324.2M $413.9M
YoY Change -21.77% 79.61% 226.68%
Other Assets $42.57M $23.94M $19.80M
YoY Change 114.99% 5.56% 21.87%
Total Long-Term Assets $626.4M $577.8M $647.1M
YoY Change -3.19% 46.68% 109.1%
TOTAL ASSETS
Total Short-Term Assets $1.725B $1.323B $758.7M
Total Long-Term Assets $626.4M $577.8M $647.1M
Total Assets $2.352B $1.901B $1.406B
YoY Change 67.29% 69.98% 53.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.89M $12.87M $12.30M
YoY Change 4.8% -5.79% 83.31%
Accrued Expenses $86.40M $55.20M $41.30M
YoY Change 109.2% 11.52% -17.56%
Deferred Revenue $22.58M $25.67M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.300M $1.100M $800.0K
YoY Change 62.5%
Total Short-Term Liabilities $131.6M $95.61M $76.80M
YoY Change 71.35% 28.28% 13.62%
LONG-TERM LIABILITIES
Long-Term Debt $153.7M $154.7M $154.2M
YoY Change -0.32% 28.81% 54.2%
Other Long-Term Liabilities $2.634M $2.780M $33.40M
YoY Change -92.11% 2216.67% -40.57%
Total Long-Term Liabilities $2.634M $2.780M $187.6M
YoY Change -98.6% 2216.67% 20.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $131.6M $95.61M $76.80M
Total Long-Term Liabilities $2.634M $2.780M $187.6M
Total Liabilities $351.0M $277.1M $264.4M
YoY Change 32.75% 11.44% 18.19%
SHAREHOLDERS EQUITY
Retained Earnings -$1.350B -$913.8M
YoY Change 58.19%
Common Stock $547.0K $494.0K
YoY Change 21.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.001B $1.623B $1.141B
YoY Change
Total Liabilities & Shareholders Equity $2.352B $1.901B $1.406B
YoY Change 67.29% 69.98% 53.09%

Cashflow Statement

Concept 2018 Q3 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$145.5M -$117.2M -$78.81M
YoY Change 84.61% 64.27% 2.31%
Depreciation, Depletion And Amortization $4.410M $3.640M $3.620M
YoY Change 21.82% 44.44% 52.1%
Cash From Operating Activities -$74.48M -$95.38M -$56.33M
YoY Change 32.22% 38.01% 42.82%
INVESTING ACTIVITIES
Capital Expenditures -$22.15M -$18.83M -$3.900M
YoY Change 467.95% 44.62% -56.42%
Acquisitions
YoY Change
Other Investing Activities $56.02M $46.42M -$394.9M
YoY Change -114.19% -138.84% -676.64%
Cash From Investing Activities $33.87M $27.59M -$398.8M
YoY Change -108.49% -120.81% -769.77%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 658.8M 588.3M 6.120M
YoY Change 10664.54% 145.37% 151.85%
NET CHANGE
Cash From Operating Activities -74.48M -95.38M -56.33M
Cash From Investing Activities 33.87M 27.59M -398.8M
Cash From Financing Activities 658.8M 588.3M 6.120M
Net Change In Cash 618.2M 520.5M -449.0M
YoY Change -237.68% 1266.25% -2092.85%
FREE CASH FLOW
Cash From Operating Activities -$74.48M -$95.38M -$56.33M
Capital Expenditures -$22.15M -$18.83M -$3.900M
Free Cash Flow -$52.33M -$76.55M -$52.43M
YoY Change -0.19% 36.48% 71.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21763000
CY2018Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22575000
CY2018Q3 blue Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
7842000
CY2018Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
22256000
CY2018Q3 blue Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
37676000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
324193000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
723141000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
531604000
CY2018Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
20017000
CY2018Q3 blue Tenant Improvement Costs Reimbursable Current
TenantImprovementCostsReimbursableCurrent
19000
CY2018Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
24133000
CY2018Q3 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
5901000
CY2017Q4 blue Receivables And Other Current Assets
ReceivablesAndOtherCurrentAssets
8377000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
1725348000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
323772000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
232863000
CY2018Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
14109000
CY2018Q3 us-gaap Goodwill
Goodwill
13128000
CY2018Q3 us-gaap Assets
Assets
2351789000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12891000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42569000
CY2018Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
88335000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
25674000
CY2018Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3074000
CY2018Q3 blue Financing Lease Obligation Noncurrent
FinancingLeaseObligationNoncurrent
153716000
CY2018Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2634000
CY2018Q3 us-gaap Liabilities
Liabilities
350999000
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
547000
CY2018Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3355491000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5463000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1349785000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
2000790000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2351789000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54678000
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54678000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
11528000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180464000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
120621000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
64463000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1100000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
67000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1520000
CY2018Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2017Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
blue:LicenseAndRoyaltyMember
CY2018Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
47000
CY2017Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-258000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
843000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
205000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
161347000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
85369000
us-gaap Operating Expenses
OperatingExpenses
450398000
us-gaap Operating Expenses
OperatingExpenses
246652000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-149819000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77658000
us-gaap Operating Income Loss
OperatingIncomeLoss
-415062000
us-gaap Operating Income Loss
OperatingIncomeLoss
-215393000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4591000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7711000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35336000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
31259000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116744000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
61545000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
328867000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44527000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22982000
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1155000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
8415000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1842000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-252000
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1180000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145480000
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-78805000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-406602000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-218415000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-145480000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-78805000
us-gaap Net Income Loss
NetIncomeLoss
-406602000
us-gaap Net Income Loss
NetIncomeLoss
-218415000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.73
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.73
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.95
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.14
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
53277000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
45648000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51130000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42524000
CY2018Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-66000
CY2017Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-683000
blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-1255000
blue Other Comprehensive Income Loss Unrealized Gain Loss And Foreign Currency Translation Adjustment On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeLossUnrealizedGainLossAndForeignCurrencyTranslationAdjustmentOnSecuritiesArisingDuringPeriodNetOfTax
-949000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-66000
CY2017Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-683000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1255000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-949000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-145546000
CY2017Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-79488000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-407857000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-219364000
CY2018Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
CY2017Q3 blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
blue Other Comprehensive Income Loss Unrealized Gain Loss On Securities And Foreign Currency Translation Adjustments Arising During Period Tax
OtherComprehensiveIncomeLossUnrealizedGainLossOnSecuritiesAndForeignCurrencyTranslationAdjustmentsArisingDuringPeriodTax
0
us-gaap Profit Loss
ProfitLoss
-406602000
us-gaap Profit Loss
ProfitLoss
-218415000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
843000
blue Fair Value Of Contingent Consideration Non Cash
FairValueOfContingentConsiderationNonCash
-1460000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12613000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9899000
us-gaap Share Based Compensation
ShareBasedCompensation
80849000
us-gaap Share Based Compensation
ShareBasedCompensation
38953000
us-gaap Other Noncash Expense
OtherNoncashExpense
3106000
us-gaap Other Noncash Expense
OtherNoncashExpense
2545000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19014000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12865000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-493000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-447000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
31466000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6468000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185174000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-31981000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
3084000
blue Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
-45518000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-283695000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
966000000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
251724000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2770000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42844000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
43408000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
827163000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
621004000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
631680000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
320190000
blue Payments To Acquire Other Investments And Investment Receivable
PaymentsToAcquireOtherInvestmentsAndInvestmentReceivable
20017000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-258344000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-344222000
blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
649367000
blue Proceeds From Public Offering Of Common Stock Net Of Issuance Costs
ProceedsFromPublicOfferingOfCommonStockNetOfIssuanceCosts
436805000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1074000
blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
3098000
blue Proceeds From Reimbursement Of Assets Under Financing Lease Obligation
ProceedsFromReimbursementOfAssetsUnderFinancingLeaseObligation
38021000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
728000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
315000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
29550000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14406000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
735771000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
487843000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
193732000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-41553000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
772268000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
293277000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1740000
blue Assets Acquired Under Financing Lease Obligation
AssetsAcquiredUnderFinancingLeaseObligation
2467000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
49000
blue Receivable For Stock Option Exercise
ReceivableForStockOptionExercise
845000
blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
14000
blue Tenant Improvements Under Financing Lease Included In Tenant Improvements Receivable
TenantImprovementsUnderFinancingLeaseIncludedInTenantImprovementsReceivable
2013000
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bluebird bio, Inc. (the &#8220;Company&#8221; or &#8220;bluebird&#8221;) was incorporated in Delaware on April&#160;16, 1992, and is headquartered in Cambridge, Massachusetts. The Company researches, develops, manufactures and plans to commercialize gene therapies for the treatment of severe genetic diseases and cancer. Since its inception, the Company has devoted substantially all of its resources to its research and development efforts relating to its product candidates, including activities to manufacture product candidates, conduct clinical studies of its product candidates, perform preclinical research to identify new product candidates and provide general and administrative support for these operations.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s clinical programs in severe genetic diseases include its LentiGlobin<sup style="font-size:85%; vertical-align:top">&#174;</sup> product candidate to treat transfusion-dependent &#946;-thalassemia, or TDT, and to treat sickle cell disease, or SCD, and its Lenti-D<sup style="font-size:85%; vertical-align:top">TM</sup> product candidate to treat cerebral adrenoleukodystrophy, or CALD, a rare hereditary neurological disorder. The Company&#8217;s programs in oncology are built upon its leadership in lentiviral gene delivery and T cell engineering, with a focus on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121 and bb21217, which are product candidates in oncology under the Company&#8217;s collaboration arrangement with Celgene Corporation (&#8220;Celgene&#8221;), are CAR T cell product candidates for the treatment of multiple myeloma. Refer to Note 9, &#8220;<font style="font-style:italic;">Collaborative arrangements</font>&#8221; for further discussion of the Company&#8217;s collaboration with Celgene.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2018, the Company had cash, cash equivalents and marketable securities of $2.0 billion. Although the Company has incurred recurring losses and expects to continue to incur losses for the foreseeable future, the Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund current operations for at least the next twelve months.&nbsp;&nbsp;</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:2.27%;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the <font style="color:#000000;">reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially</font> from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, among others: subsequent fair value estimates used to assess potential impairment of long-lived assets, including goodwill and intangible assets, financing lease obligation, contingent consideration, stock-based compensation expense, accrued expenses, revenue and income taxes.</p></div>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
1992-04-16
CY2018Q3 us-gaap Investments And Cash
InvestmentsAndCash
2000000000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
45344000
CY2018Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
31468000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-943183000
us-gaap Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment
ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment
Under ASC 605, the Company accounted for contract modifications to the Celgene collaboration as they occurred and the accounting for those changes was prospective in nature. Through the application of the practical expedient discussed above in connection with the adoption of Topic 606, the Company reflected the aggregate effect of all modifications to the Celgene collaboration when identifying the satisfied and unsatisfied performance obligations, determining the transaction price, and allocating the transaction price. As a result, although the performance obligations identified under Topic 606 were generally consistent with the units of account identified under ASC 605, the timing of the allocation of the transaction price to the identified performance obligations under Topic 606 differed from the allocations of consideration under ASC 605. Accordingly, the transaction price ultimately allocated to each performance obligation under Topic 606 differed from the amounts allocated under ASC 605.
CY2018Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7900000
CY2018Q3 blue Restricted Cash Included In Receivables And Other Current Assets
RestrictedCashIncludedInReceivablesAndOtherCurrentAssets
100000
CY2018Q3 blue Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
13763000
CY2017Q3 blue Restricted Cash Included In Restricted Cash And Other Non Current Assets
RestrictedCashIncludedInRestrictedCashAndOtherNonCurrentAssets
13762000
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1051617000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
859375000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4705000
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3579000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1046913000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
855797000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
0
CY2018Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
640100000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
704100000
CY2018Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
392500000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
134400000
CY2018Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
1800000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3300000
CY2018Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2900000
CY2017Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
300000
CY2018Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2017Q4 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
blue Additional Cash Cash Equivalent And Marketable Securities Related Text
AdditionalCashCashEquivalentAndMarketableSecuritiesRelatedText
90 days or less
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
258502000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
215455000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
25639000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15849000
CY2018Q3 blue Accrued Goods And Services
AccruedGoodsAndServices
62466000
CY2017Q4 blue Accrued Goods And Services
AccruedGoodsAndServices
29533000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
21139000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19657000
CY2018Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2177000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1402000
CY2018Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1318000
CY2017Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1051000
CY2018Q3 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
608000
CY2017Q4 blue Accrued License And Milestone Fees
AccruedLicenseAndMilestoneFees
4584000
CY2018Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
627000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
838000
CY2016Q4 blue Contractual Obligation Agreement Period
ContractualObligationAgreementPeriod
P5Y
CY2016Q4 blue Contractual Obligation Agreement Renewal Period
ContractualObligationAgreementRenewalPeriod
P3Y
CY2018Q3 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
1000000
CY2016Q4 blue Contractual Obligation Fees
ContractualObligationFees
3000000
CY2016Q4 blue Contractual Obligation Advance Fees Payment
ContractualObligationAdvanceFeesPayment
2000000
blue Contractual Obligation Termination Description
ContractualObligationTerminationDescription
The Company may terminate this agreement with twelve months’ notice and a one-time termination fee.
blue Decrease In Letter Of Credit Related To New Lease Agreement
DecreaseInLetterOfCreditRelatedToNewLeaseAgreement
9200000
CY2018Q3 us-gaap Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year
ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear
4000000
CY2018Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
23000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
32000000
CY2017Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3200000
CY2017Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2017Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
569800000
CY2018Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
300000
CY2018Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
185.00
CY2018Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
48700000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
2000000
CY2017Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Other Increases Decreases In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
1600000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1600000
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29797000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
80849000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13983000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38953000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3755000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1416000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
535000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
97000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4539000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2035000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4507000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
67.91
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
193.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
52.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
134.63
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
107.28
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
60.91
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
107.32
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
28300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5483000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4482000

Files In Submission

Name View Source Status
0001564590-18-026258-index-headers.html Edgar Link pending
0001564590-18-026258-index.html Edgar Link pending
0001564590-18-026258.txt Edgar Link pending
0001564590-18-026258-xbrl.zip Edgar Link pending
blue-10q_20180930.htm Edgar Link pending
blue-20180930.xml Edgar Link completed
blue-20180930.xsd Edgar Link pending
blue-20180930_cal.xml Edgar Link unprocessable
blue-20180930_def.xml Edgar Link unprocessable
blue-20180930_lab.xml Edgar Link unprocessable
blue-20180930_pre.xml Edgar Link unprocessable
blue-ex311_8.htm Edgar Link pending
blue-ex312_6.htm Edgar Link pending
blue-ex321_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending